Skip to main content

FDA Approves New Injectable Drug to Treat Schizophrenia

On October 5, the US Food and Drug Administration (FDA) approved Aristada (aripiprazole lauroxil) extended release injection to treat adults with schizophrenia. Aristada is administered by a healthcare professional every 4 to 6 weeks using an injection in the arm or buttocks.

Schizophrenia is a chronic, severe and disabling brain disorder affecting about 1% of Americans. Typically, symptoms are first seen in adults aged <30 years, and include hearing voices, believing other people are reading their minds or controlling their thoughts, and being suspicious or withdrawn.

“Long-acting medications to treat schizophrenia can improve the lives of patients,” said Mitchell Mathis, MD, director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research. “Having a variety of treatment options and dosage forms available for patients with mental illness is important so that a treatment plan can be tailored to meet the patient’s needs.”

The efficacy of Aristada was demonstrated in part by a 12-week clinical trial in 622 participants. In participants with acute schizophrenia who had been stabilized with oral aripiprazole, Aristada was found to maintain the treatment effect compared to a placebo.

Aristada and other atypical antipsychotic drugs used to treat schizophrenia have Boxed Warnings alerting healthcare professionals about an increased risk of death associated with the off-label use of these drugs to treat behavioral problems in older people with dementia-related psychosis. No drug in this class is approved to treat patients with dementia-related psychosis. Aristada must be dispensed with a patient Medication Guide that describes important information about the drug’s uses and risks.

The most common side effect reported by participants receiving Aristada in clinical trials was feeling the urge to move constantly (akathisia).

Aristada is manufactured by Alkermes, Inc. of Waltham, MA.

US Food and Drug Administration. FDA approves new injectable drug to treat schizophrenia. Updated October 6, 2015.

Related Items
Tornado Sweeps Through Pfizer’s Storage and Manufacturing Facility
Web Exclusives published on July 28, 2023 in In the News
Acceptance of Artificial Intelligence in Healthcare Is Making Inroads
Web Exclusives published on July 27, 2023 in In the News
CMS Expands Access to Telehealth Benefits During COVID-19 Outbreak
Web Exclusives published on March 19, 2020 in Health Policy and Reform, In the News
Tazverik Receives FDA Approval as First Treatment Specifically for Metastatic or Locally Advanced Epithelioid Sarcoma
Web Exclusives published on January 28, 2020 in FDA Approvals, In the News, Select Drug Profiles
Mixed Findings in Annual Cancer Statistics Report
Web Exclusives published on January 21, 2020 in FDA Approvals, In the News, Select Drug Profiles
Last modified: August 30, 2021